[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-myocardial-infarction-with-st-elevation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-myocardial-infarction-with-st-elevation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,78,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100639639","phase-2-recombinant-human-thymosin-beta-4-for-injectionnl005-for-acute-myocardial-infarction-100639639",false,"NCT07586865","Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase IIc Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Recombinant Human Thymosin Beta 4 Injection (NL005) in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Willing and able to provide written informed consent (by the participant or legally authorized representative)\n* Aged 18 to 75 years old, any sex\n* Diagnosis of ST-segment elevation myocardial infarction (STEMI) with electrocardiogram (ECG) meeting protocol-specified ST-elevation criteria, and scheduled to undergo primary percutaneous coronary intervention (PCI)\n* OR, regardless of ECG criteria, the participant has a completely or nearly completely blocked (TIMI flow grade 0 or 1) proximal or mid left anterior descending (LAD) coronary artery as the single culprit vessel\n* The blocked LAD artery has no visible collateral blood supply from other coronary arteries (Rentrop grade 0)\n* Total myocardial ischemic time (time from chest pain onset to guidewire passage during PCI) meets one of the following: 1. More than 2 hours and less than 6 hours of ischemic time, with either post-PCI LAD TIMI flow grade of 2 or less, or left ventricular ejection fraction (LVEF) of 50% or lower measured by cardiac ultrasound during PCI hospitalization; 2. Between 6 and 24 hours of ischemic time (inclusive)\n* Males and females of childbearing potential must agree to use adequate contraception (such as hormonal or barrier methods, or abstinence) throughout the study\n\nExclusion Criteria:\n\n* Prior history of acute myocardial infarction, chronic total coronary occlusion, coronary thrombolysis, PCI, or coronary artery bypass graft surgery\n* Diagnosis of severe acute heart failure (Killip class III or higher) or chronic heart failure (NYHA functional class III or higher)\n* Severe, uncontrolled arrhythmia that cannot be corrected\n* Presence of aortic dissection\n* Severe liver or kidney dysfunction\n* History of stroke within the past 6 months\n* Current or past diagnosis of any malignancy\n* Blood pressure that remains at or above 180 mmHg systolic and\u002For 110 mmHg diastolic despite adequate antihypertensive treatment\n* History of clinically significant allergic reaction, especially known allergy to protein or biologic drugs\n* Participation in another clinical study within 3 months before screening\n* Unable to undergo cardiac magnetic resonance (CMR) imaging (e.g., due to implanted metal devices, severe claustrophobia, or other contraindications)\n* Any other condition that the investigator believes makes participation unsuitable (for example, the need for urgent or planned revascularization of non-LAD coronary arteries within 3 months)","ALL","18 Years","75 Years",{"count":20,"type":21},189,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this phase IIc clinical trial is to learn if recombinant human thymosin beta 4 injection (NL005) works to treat heart damage in people who have had a serious type of heart attack called ST-segment elevation myocardial infarction (STEMI) and have been treated with emergency percutaneous coronary intervention (PCI, a procedure to open the blocked artery). It will also learn about the safety of NL005. The main questions it aims to answer are:\n\n* Does NL005 lower the size of permanent heart muscle damage measured by cardiac magnetic resonance (CMR) scan 90 days after treatment?\n* What medical problems do participants have when taking NL005?\n\nResearchers will compare two different doses of NL005 to a placebo (a look-alike substance that contains no drug) to see if NL005 works better to reduce heart damage caused by the heart attack.\n\nParticipants will:\n\n* Receive NL005 or placebo through a vein within 4 hours after the PCI procedure, then once a day for 7 days\n* Stay in the hospital for the first week for monitoring, blood draws, and electrocardiograms (heart tracings)\n* Have a CMR scan on Day 6 and Day 90 to measure the size of the heart injury\n* Return to the hospital for checkups on Day 30 and Day 90\n* Be contacted by the study team (by phone or online) 3 times during the first year and come back to the hospital on Day 360 to check long-term recovery",[27,28,29,30,31],"Acute Myocardial Infarction (AMI)","Acute Myocardial Infarction of Anterior Wall","Acute Myocardial Infarction With ST Elevation","Acute Myocardial Infarction of Left Ventricle","Acute Myocardial Infarction With ST Segment Elevation",[33,34,35],"AMI","CMR","cardioprotective","NOT_YET_RECRUITING","2026-05-08",{"date":39,"type":40},"2026-05-14","ACTUAL",{"date":42,"type":21},"2026-05-18",{"date":44,"type":21},"2028-05-17",{"name":46,"class":47},"Beijing Northland Biotech. Co., Ltd.","INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":48},"100615639","phase-3-effect-of-glp-1-and-antidiabetic-sglt2-agents-for-myocardial-infarction-and-ultrasensitive-inflammatory-surveillance-galactus-trial-100615639","NCT07295223","Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)","GLP-1 and Antidiabetic SGLT2 Agents for Myocardial Infarction and Ultrasensitive Inflammatory Surveillance: An Open-Label Pilot Study","GALACTUS","Inclusion Criteria:\n\n* Criteria for the fourth definition of acute myocardial infarction with ST-segment elevation.\n* Diagnosed with type 2 diabetes.\n* Initial serum high-sensitivity CRP value \\> 2.0 mg\u002FL.\n* Clinically obese.\n* LVEF \\>50%.\n\nExclusion Criteria:\n\n* Patients who have recently received immunosuppressive therapy\n* Patients with a history of ischemic heart disease\n* Known allergy to any of the medications used\n* Use of any of the study drugs more than 6 months prior to randomization\n* Patients experiencing diabetic ketoacidosis\n* Patients with hemodynamic instability (mean arterial pressure \\\u003C60 mmHg while on vasopressors)\n* Pregnant women\n* Patients with a history or current diagnosis of cancer\n* Patients with documented active infections, such as pneumonia or urinary tract infections\n* Patients with pancreatitis",{"count":58,"type":21},44,[60],"PHASE3","The primary risk factor for coronary artery disease is atherosclerosis, with inflammation playing a crucial role in the development and progression of this condition. It has now been proven that inflammation is key in the development of complications after an acute myocardial infarction. These complications can be immediate and mechanical, such as ventricular wall rupture and ventricular arrhythmia, or long-term, presenting as major cardiovascular events like heart failure.\n\nDuring acute myocardial infarction (AMI), circulating high-sensitivity CRP levels increase approximately 6 hours after the onset of ischemia. CRP levels measured between 24 and 72 hours after symptom onset are a significant prognostic marker for one-year outcomes. Higher high-sensitivity CRP levels at the time of AMI are linked to more severe coronary atherosclerotic lesions seen on angiography and lower LVEF one month after the event. A serum high-sensitivity CRP concentration greater than 10 mg\u002FL after an AMI indicates inflammation, reflecting myocardial necrosis, plaque rupture, and acute thrombosis. In patients with AMI, persistent or increasing CRP levels are strongly associated with a higher risk of all-cause and non-cardiovascular death, especially when inflammation (CRP \\> 2.0 mg\u002FL) continues for a year.\n\nAside from reperfusion therapy, very few pharmacological approaches have been used to reduce inflammation after AMI. One such approach was the use of colchicine in the COVERT-MI randomized, double-blind, multicenter trial. This trial compared five days of oral colchicine with a placebo and found no difference in infarct size between the groups at five days or three months, as measured by cardiac magnetic resonance imaging.\n\nSGLT-2 inhibitors are drugs that have revolutionized the management of cardiovascular diseases, offering proven benefits for patients with heart failure and notable nephroprotective effects. However, their use after acute myocardial infarction has not yet been sufficiently established, as the only two published clinical trials so far failed to meet their primary goal of reducing hospitalizations for heart failure. Additionally, evidence of their use in post-AMI inflammation exists only in experimental studies. In experimental studies, SGLT2 global-knockout (KO) mice were used to demonstrate that dapagliflozin significantly influences cardiac fibrosis and inflammation, and markedly alters the gene expression profiles of macrophages and fibroblasts. Moreover, dapagliflozin directly inhibited macrophage-mediated inflammation, thereby suppressing cardiac fibroblast activation.\n\nSimilarly, only experimental studies have shown that semaglutide decreases elevated levels of TNF-α, IL-6, ROS, and MDA in the serum and cardiac tissues of obese mice. By lowering the expression of Cxcl2, S100a8, and S100a9 in neutrophils, semaglutide may help reduce cardiac inflammation and oxidative stress.\n\nTherefore, the objective of this study is to compare the effects of dapagliflozin and semaglutide on inflammatory markers (hs-CRP and IL-6) in patients with acute ST-segment elevation myocardial infarction.",[29],[64,65,66,67],"STEMI","Semaglutide","Dapagliflozin","High-sensitivity PCR","RECRUITING","2025-12-30",{"date":71,"type":40},"2026-01-05",{"date":69,"type":40},{"date":74,"type":21},"2026-09",{"name":76,"class":77},"Instituto Mexicano del Seguro Social","OTHER_GOV",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":48},"100603695","artificial-intelligence-system-for-early-warning-of-adverse-events-in-acute-myocardial-infarction-100603695","NCT07139860","Artificial Intelligence System for Early Warning of Adverse Events in Acute Myocardial Infarction","AIEWAEAMI","Inclusion Criteria:\n\n* 1\\. Hospitalized patients who meet the diagnostic criteria for acute myocardial infarction. 2. Patients who agree to participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Patients with terminal malignant tumors and an expected survival time of less than 3 months. 2. Patients with complete disability and inability to communicate. 3. Patients unable to comply with follow-up.",{"count":86,"type":21},1400,"1 Year","OBSERVATIONAL","The goal of this observational study is to learn about the effectiveness of an artificial intelligence-based early warning system for predicting adverse events in patients with acute myocardial infarction (AMI). The main question it aims to answer is:\n\nDoes an AI-based early warning system improve the assessment and prediction of adverse events across the full course of AMI care (from prevention to diagnosis, treatment, and rehabilitation)?\n\nParticipants who are receiving routine medical care for AMI in tertiary hospitals will have their multimodal medical data (clinical records, diagnostic tests, imaging, treatment pathways) collected and analyzed. Data will be integrated using innovative cross-modal representation methods and predictive models. The study will follow patients during their hospital stay and subsequent clinical follow-up to evaluate the feasibility, accuracy, and clinical value of the AI-based early warning system.",[29,91,92],"Intelligent Management Platform","Early Warning","2025-08-22",{"date":95,"type":40},"2025-08-24",{"date":97,"type":40},"2022-11-26",{"date":99,"type":21},"2026-12-31",{"name":101,"class":102},"Hui Chen","OTHER",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":48},"100472393","glucose-monitoring-after-acute-myocardial-infarct-in-people-with-diabetes-100472393","NCT05431296","Glucose Monitoring After Acute Myocardial Infarct in People With Diabetes","GLAM","Inclusion Criteria:\n\nFrom the Hammersmith Hospital In-patient Cardiology Services:\n\n* Adults aged \\>18 years\n* Known or newly diagnosed type 2 diabetes\n* Taking one or more oral hypoglycaemic agent, GLP1 receptor analogue and\u002For insulin\n* Admitted to Hammersmith Hospital cardiology inpatient services with ACS\n* Raised blood troponin level on admission\n\nFrom Imperial College Healthcare Trust Diabetes and Cardiology Clinics:\n\n* Adults aged \\>18 years\n* Known type 2 diabetes\n* Previous acute coronary syndrome within the last 10 years but \\> 6 months ago\n* Taking one or more oral hypoglycaemic agent and \u002For GLP1 receptor analogue, and\u002For insulin\n\nExclusion Criteria:\n\nFrom the Hammersmith Hospital In-patient Cardiology Services:\n\n* HbA1c \\\u003C48mmol\u002Fmol\n* People who have previously had bariatric surgery\n* People taking hydroxyurea\n* People who undergo haemodialysis or peritoneal dialysis\n* Unable to participate due to other factors, as assessed by the Chief Investigators\n* Pregnancy as determined by clinical team\n* Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year\n\nFrom Imperial College Healthcare Trust Diabetes and Cardiology Clinics:\n\n* HbA1c \\\u003C48mmol\u002Fmol\n* People who have previously had bariatric surgery\n* People taking hydroxyurea\n* People who undergo haemodialysis or peritoneal dialysis\n* Unable to participate due to other factors, as assessed by the Chief Investigators\n* Pregnancy as determined by clinical team\n* Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year\n* Previous acute coronary syndrome more than 10 years ago or within the last 6 months\n\nWithdrawal criteria\n\n* The subject has a serious event related to the study\n* Investigated initiated discontinuation of study due to participation or equipment concerns\n* Withdrawal of consent",{"count":111,"type":21},160,[113],"NA","Glucose monitoring after Acute Myocardial infarct in people with diabetes is a Dexcom funded study that is investigating whether the use of continuous glucose monitors (Dexcom ONE model) in people with type 2 diabetes facilitates time in glycaemic range in the 6 months after an acute myocardial infarction. As an exploratory outcome it will investigate whether time in glycaemic range is associated with changes in mortality and major adverse cardiac events in the 6 months after acute myocardial infarct.",[116,117,29,118],"Type 2 Diabetes","Acute Myocardial Infarction","Diabetes Complications","2024-07-02",{"date":121,"type":40},"2024-07-03",{"date":123,"type":40},"2023-02-07",{"date":125,"type":21},"2025-02",{"name":127,"class":102},"Imperial College London"]